HealthQuill Articles by: HealthQuill
The imperative for the global governance of artificial intelligence (AI) is “irrefutable” as its accelerating development concentrates power and wealth on a global scale, according to a UN report.
Drugs Health Pharma

UN report calls for global governance of artificial intelligence

The imperative for the global governance of artificial intelligence (AI) is “irrefutable” as its accelerating development concentrates power and wealth on a global

Read More
Vanda Pharmaceuticals Inc’s gastroparesis drug to treat a serious stomach condition was rejected by the Food and Drug Administration (FDA), which asked for additional studies, according to a company statement.
Drugs Health Pharma

FDA faces Vanda’s ire as it rejects firm’s gastroparesis drug application

Vanda Pharmaceuticals Inc’s gastroparesis drug to treat a serious stomach condition was rejected by the Food and Drug Administration (FDA), which asked for

Read More
Researchers supported by the National Institutes of Health stopped a trial after they gathered sufficient evidence that an experimental drug to treat a rare bleeding disorder was safe and effective, according to a statement.
Drugs Health Pharma

Bleeding disorder trial halted after pomalidomide drug proves efficacy

Researchers supported by the National Institutes of Health stopped a trial after they gathered sufficient evidence that an experimental drug to treat a

Read More
The US-based Biomedical Advanced Research and Development Authority will help Switzerland’s Basilea Pharmaceutica Ltd., to develop antifungals and antibacterials with an initial funding of $29 million.
Drugs Health Pharma

Basilea in $268m pact with BRDA for antifungals, antibacterials

The US-based Biomedical Advanced Research and Development Authority will help Switzerland’s Basilea Pharmaceutica Ltd., to develop antifungals and antibacterials with an initial funding

Read More
Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug Administration.
Drugs Health Pharma

Merck’s advanced lung cancer drug gets US drug regulator’s nod

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug

Read More
Surgery-free cataracts may be possible in the future after researchers at the National Institutes of Health discovered a protein that can reverse and manage the clouding of the eye’s lens or lead to the development of a drug.
Drugs Health Pharma

Protein discovery in animal studies holds hope for surgery-free cataract

Surgery-free cataracts may be possible in the future after researchers at the National Institutes of Health discovered a protein that can reverse and

Read More
US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.
Drugs Health Pharma

Organon & Co to buy Riovant’s arm Dermavant Sciences for $1.2 billion

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More
Antibiotic-resistant infections may kill 39.1 million people in the next 25 years equating to three deaths a minute, a global study finds.
Drugs Health Pharma

Antimicrobial resistance may kill 39.1 million people by 2050: GRAM

Antibiotic-resistant infections may kill 39.1 million people in the next 25 years equating to three deaths a minute, a global study finds.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a

Read More